BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Uterine cancer AND FBXW7, AGO, 55294, ENSG00000109670, FLJ11071, SEL-10, CDC4, FBXW6, SEL10, FBW7, DKFZp686F23254, FBX30 AND Clinical Outcome
7 results:

  • 1. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
    Yoshimoto Y; Sasaki Y; Murata K; Noda SE; Miyasaka Y; Hamamoto J; Furuya M; Hirato J; Suzuki Y; Ohno T; Tokino T; Oike T; Nakano T
    Gynecol Oncol; 2020 Nov; 159(2):546-553. PubMed ID: 32951893
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Immune Signature-Based Subtypes of Cervical Squamous Cell Carcinoma Tightly Associated with Human Papillomavirus Type 16 Expression, Molecular Features, and clinical outcome.
    Lu X; Jiang L; Zhang L; Zhu Y; Hu W; Wang J; Ruan X; Xu Z; Meng X; Gao J; Su X; Yan F
    Neoplasia; 2019 Jun; 21(6):591-601. PubMed ID: 31055200
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [The clinical characteristics of pulmonary benign metastasizing leiomyoma].
    Wang HP; Shi JH; Zhang L
    Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):490-494. PubMed ID: 28693056
    [No Abstract]    [Full Text] [Related]  

  • 4. Rapid developing basaloid squamous cell carcinoma of the uterine cervix in a young adult Taiwanese.
    Tsai HJ; Liou B; Li MC
    Malays J Pathol; 2013 Dec; 35(2):177-80. PubMed ID: 24362481
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-ago phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
    Braicu EI; Fotopoulou C; Chekerov R; Richter R; Blohmer J; Kümmel S; Stamatian F; Yalcinkaya I; Mentze M; Lichtenegger W; Sehouli J
    Cytokine; 2013 Mar; 61(3):755-8. PubMed ID: 23415672
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation.
    Suehiro Y; Okada T; Okada T; Anno K; Okayama N; Ueno K; Hiura M; Nakamura M; Kondo T; Oga A; Kawauchi S; Hirabayashi K; Numa F; Ito T; Saito T; Sasaki K; Hinoda Y
    Clin Cancer Res; 2008 Jun; 14(11):3354-61. PubMed ID: 18519763
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
    Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
    Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.